Fractyl Health spotlights REMAIN-1 data showing Revita maintains 84% of GLP-1 weight loss in optimized cohort

Fractyl Health set a Sept. 1, 2026 virtual Commercial Strategy Day outlining a proposed go-to-market plan for Revita, a one-time post-GLP-1 therapy.

One-year randomized study results were already presented, showing Revita supported weight maintenance versus a sham procedure in a targeted patient group.

Management will frame Revita as a procedural “off-ramp” for patients discontinuing GLP-1 drugs, addressing a large US treated population.

Focus shifts to a six-month topline readout from the REMAIN-1 Pivotal Cohort expected in early Q4 2026.

Regulatory plans include a potential FDA De Novo marketing application submission anticipated in late Q4 2026.